» Articles » PMID: 38771477

Utilities for Complications Associated with Type 2 Diabetes: A Review of the Literature

Overview
Journal Adv Ther
Date 2024 May 21
PMID 38771477
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Utility values are used in health economic modeling analyses of type 2 diabetes (T2D) to quantify the effect of acute and long-term complications on quality of life (QoL). For accurate modeling projections, it is important that the utility values used are up to date, accurate and representative of the simulated model cohort.

Methods: A literature review was performed to identify utility values for health states representing acute and chronic T2D-related complications including cardiovascular complications, stroke, renal disease, ophthalmic complications, neuropathy, diabetic foot, amputation and hypoglycemia. Searches were performed using the PubMed, Embase and Cochrane Library databases and limited to articles published since 2010. Supplementary searches were performed to identify data published at congresses in 2019-2023.

Results: A total of 54 articles were identified that reported utility values for T2D-related complications. The most frequently used elicitation method/instrument was the EQ-5D (n = 42 studies) followed by the Short Form-6 dimensions (n = 6), time tradeoff (n = 5), the Health Utilities Index Mark 2 or Mark 3 (n = 2), 15D (n = 1), visual analog scale (n = 1) and standard gamble (n = 1). Stroke and amputation were consistently associated with the largest decrements in QoL. There is a lack of published data that distinguishes between severity of several complications including renal disease, retinopathy and neuropathy.

Conclusions: Diabetes-related complications can have a profound impact on QoL; therefore, it is important that these are captured accurately and appropriately in health economic models. Recently published utility values for diabetes-related complications that can be used to inform health economic models are summarized here.

References
1.
Brooks R, Boye K, Slaap B . EQ-5D: a plea for accurate nomenclature. J Patient Rep Outcomes. 2020; 4(1):52. PMC: 7334333. DOI: 10.1186/s41687-020-00222-9. View

2.
Brazier J, Ara R, Azzabi I, Busschbach J, Chevrou-Severac H, Crawford B . Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report. Value Health. 2019; 22(3):267-275. DOI: 10.1016/j.jval.2019.01.004. View

3.
Beaudet A, Clegg J, Thuresson P, Lloyd A, McEwan P . Review of utility values for economic modeling in type 2 diabetes. Value Health. 2014; 17(4):462-70. DOI: 10.1016/j.jval.2014.03.003. View

4.
Kim S, Won J, Kwon H, Kim C, Lee J, Park T . Prevalence and clinical implications of painful diabetic peripheral neuropathy in type 2 diabetes: results from a nationwide hospital-based study of diabetic neuropathy in Korea. Diabetes Res Clin Pract. 2014; 103(3):522-9. DOI: 10.1016/j.diabres.2013.12.003. View

4.
Shi L, Shao H, Zhao Y, Thomas N . Is hypoglycemia fear independently associated with health-related quality of life?. Health Qual Life Outcomes. 2014; 12:167. PMC: 4268814. DOI: 10.1186/s12955-014-0167-3. View